Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: findings from the EPICOR study.
Sinnaeve PR, Zeymer U, Bueno H, Danchin N, Medina J, Sánchez-Covisa J, Licour M, Annemans L, Jukema JW, Pocock S, Storey RF, Van de Werf F. Sinnaeve PR, et al. Among authors: van de werf f. Eur Heart J Acute Cardiovasc Care. 2015 Jun;4(3):254-62. doi: 10.1177/2048872614551544. Epub 2014 Sep 10. Eur Heart J Acute Cardiovasc Care. 2015. PMID: 25210075
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.
Giugliano RP, Roe MT, Harrington RA, Gibson CM, Zeymer U, Van de Werf F, Baran KW, Hobbach HP, Woodlief LH, Hannan KL, Greenberg S, Miller J, Kitt MM, Strony J, McCabe CH, Braunwald E, Califf RM; INTEGRITI Investigators. Giugliano RP, et al. Among authors: van de werf f. J Am Coll Cardiol. 2003 Apr 16;41(8):1251-60. doi: 10.1016/s0735-1097(03)00123-2. J Am Coll Cardiol. 2003. PMID: 12706917 Free article. Clinical Trial.
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, Ardissino D, Vahanian A, Pehrsson K, Armstrong P, Van de Werf F; ASSENT-2 Investigators. Sinnaeve P, et al. Among authors: van de werf f. Am Heart J. 2003 Jul;146(1):27-32. doi: 10.1016/S0002-8703(03)00117-0. Am Heart J. 2003. PMID: 12851604 Clinical Trial.
International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2.
Gupta M, Chang WC, Van de Werf F, Granger CB, Midodzi W, Barbash G, Pehrson K, Oto A, Toutouzas P, Jansky P, Armstrong PW; ASSENT II Investigators. Gupta M, et al. Among authors: van de werf f. Eur Heart J. 2003 Sep;24(18):1640-50. doi: 10.1016/s0195-668x(03)00433-0. Eur Heart J. 2003. PMID: 14499226 Clinical Trial.
A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U; PENTUA Investigators. Simoons ML, et al. Among authors: van de werf f. J Am Coll Cardiol. 2004 Jun 16;43(12):2183-90. doi: 10.1016/j.jacc.2004.02.051. J Am Coll Cardiol. 2004. PMID: 15193678 Free article. Clinical Trial.
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Sinnaeve PR, Alexander JH, Bogaerts K, Belmans A, Wallentin L, Armstrong P, Adgey JA, Tendera M, Diaz R, Soares-Piegas L, Vahanian A, Granger CB, Van De Werf FJ. Sinnaeve PR, et al. Am Heart J. 2004 Jun;147(6):993-8. doi: 10.1016/j.ahj.2003.12.028. Am Heart J. 2004. PMID: 15199346 Clinical Trial.
Will oral antithrombin agents replace warfarin?
Sinnaeve PR, Van de Werf FJ. Sinnaeve PR, et al. Among authors: van de werf fj. Heart. 2004 Aug;90(8):827-8. doi: 10.1136/hrt.2003.030379. Heart. 2004. PMID: 15253941 Free PMC article.
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, López-Sendón J, Laufenberg CV, Klutman M, Gowda N, Gulba D; GRACE Investigators. Collet JP, et al. Among authors: van de werf f. Eur Heart J. 2005 Nov;26(21):2285-93. doi: 10.1093/eurheartj/ehi337. Epub 2005 Jun 2. Eur Heart J. 2005. PMID: 15932908 Clinical Trial.
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial.
Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F. Janssens S, et al. Among authors: van cleemput j, van de werf f. Lancet. 2006 Jan 14;367(9505):113-21. doi: 10.1016/S0140-6736(05)67861-0. Lancet. 2006. PMID: 16413875 Clinical Trial.
757 results